202 related articles for article (PubMed ID: 15853836)
1. A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile.
Jostel A; Mukherjee A; Alenfall J; Smethurst L; Shalet SM
Clin Endocrinol (Oxf); 2005 May; 62(5):623-7. PubMed ID: 15853836
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles.
Kim SJ; Hahn SK; Kim MJ; Kim DH; Lee YP
J Control Release; 2005 May; 104(2):323-35. PubMed ID: 15907583
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys.
Sun YN; Lee HJ; Almon RR; Jusko WJ
J Pharmacol Exp Ther; 1999 Jun; 289(3):1523-32. PubMed ID: 10336548
[TBL] [Abstract][Full Text] [Related]
5. Development of a sustained-release recombinant human growth hormone formulation.
Kwak HH; Shim WS; Choi MK; Son MK; Kim YJ; Yang HC; Kim TH; Lee GI; Kim BM; Kang SH; Shim CK
J Control Release; 2009 Jul; 137(2):160-5. PubMed ID: 19332090
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone deficiency (GHD) in adult thalassaemic patients.
Scacchi M; Danesi L; Cattaneo A; Valassi E; Pecori Giraldi F; Argento C; D'Angelo E; Mirra N; Carnelli V; Zanaboni L; Cappellini MD; Cavagnini F
Clin Endocrinol (Oxf); 2007 Nov; 67(5):790-5. PubMed ID: 17608814
[TBL] [Abstract][Full Text] [Related]
7. Changes in insulin sensitivity induced by short-term growth hormone (GH) and insulin-like growth factor I (IGF-I) treatment in GH-deficient adults are not associated with changes in adiponectin levels.
Schmid C; Bianda T; Zwimpfer C; Zapf J; Wiesli P
Growth Horm IGF Res; 2005 Aug; 15(4):300-3. PubMed ID: 16054413
[TBL] [Abstract][Full Text] [Related]
8. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.
Rasmussen MH; Olsen MW; Alifrangis L; Klim S; Suntum M
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1819-29. PubMed ID: 25013997
[TBL] [Abstract][Full Text] [Related]
9. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
Bannink EM; van Doorn J; Stijnen T; Drop SL; de Muinck Keizer-Schrama SM
Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency.
Peter F; Savoy C; Ji HJ; Juhasz M; Bidlingmaier M; Saenger P
Eur J Endocrinol; 2009 Mar; 160(3):349-55. PubMed ID: 19074465
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone therapy in GH-deficient adults: continuous vs alternate-days treatment.
Giavoli C; Cappiello V; Porretti S; Ronchi CL; Orsi E; Beck-Peccoz P; Arosio M
Horm Metab Res; 2003 Sep; 35(9):557-61. PubMed ID: 14517774
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency.
Bidlingmaier M; Kim J; Savoy C; Kim MJ; Ebrecht N; de la Motte S; Strasburger CJ
J Clin Endocrinol Metab; 2006 Aug; 91(8):2926-30. PubMed ID: 16720652
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone releasing hormone plus arginine stimulation testing in young adults treated in childhood with cranio-spinal radiation therapy.
Ham JN; Ginsberg JP; Hendell CD; Moshang T
Clin Endocrinol (Oxf); 2005 May; 62(5):628-32. PubMed ID: 15853837
[TBL] [Abstract][Full Text] [Related]
15. A novel sustained-release formulation of recombinant human growth hormone and its pharmacokinetic, pharmacodynamic and safety profiles.
Wei Y; Wang Y; Kang A; Wang W; Ho SV; Gao J; Ma G; Su Z
Mol Pharm; 2012 Jul; 9(7):2039-48. PubMed ID: 22663348
[TBL] [Abstract][Full Text] [Related]
16. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency.
Yuen KC; Frystyk J; White DK; Twickler TB; Koppeschaar HP; Harris PE; Fryklund L; Murgatroyd PR; Dunger DB
Clin Endocrinol (Oxf); 2005 Oct; 63(4):428-36. PubMed ID: 16181235
[TBL] [Abstract][Full Text] [Related]
17. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome.
Grugni G; Marzullo P; Ragusa L; Sartorio A; Trifirò G; Liuzzi A; Crinò A;
Clin Endocrinol (Oxf); 2006 Oct; 65(4):492-9. PubMed ID: 16984242
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children.
Kemp SF; Fielder PJ; Attie KM; Blethen SL; Reiter EO; Ford KM; Marian M; Dao LN; Lee HJ; Saenger P
J Clin Endocrinol Metab; 2004 Jul; 89(7):3234-40. PubMed ID: 15240597
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults.
Cook DM; Biller BM; Vance ML; Hoffman AR; Phillips LS; Ford KM; Benziger DP; Illeperuma A; Blethen SL; Attie KM; Dao LN; Reimann JD; Fielder PJ
J Clin Endocrinol Metab; 2002 Oct; 87(10):4508-14. PubMed ID: 12364427
[TBL] [Abstract][Full Text] [Related]
20. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile.
Rasmussen MH; Bysted BV; Anderson TW; Klitgaard T; Madsen J
J Clin Endocrinol Metab; 2010 Jul; 95(7):3411-7. PubMed ID: 20427496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
